SCHEMBL1242600

SCHEMBL1242600

CCOC(=O)c1cc2occ(Cc3ccccc3)c2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.56
PDE3B Q13370 5/20 0.48
PDE3A Q14432 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
ERCC5 P28715 1/20 0.44
FEN1 P39748 1/20 0.44
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1245027 0.89 DAO (0.72) DAOPDE3BPDE3ASMN1; SMN2KDM4E
SCHEMBL1244068 0.85 DAO (0.46) DAOSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL1244101 0.83 DAO (0.78) DAOKDM4EALDH1A1HPGDMEN1
SCHEMBL1245049 0.82 CDK1 (0.44) DAOSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL1244837 0.78 ALDH1A1 (0.44) DAOSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL12890103 0.77 DAO (0.75) DAOALDH1A1HPGDMEN1LMNA
SCHEMBL12890086 0.77 ADORA3 (0.43) DAOSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL12777569 0.77 KDM4E (0.43) DAOSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL1243956 0.76 ALDH1A1 (0.41) DAOSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL1244597 0.76 ALDH1A1 (0.43) DAOSMN1; SMN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 US disclosed
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 US disclosed
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 US disclosed
US-20100029741-A1 FUSED HETEROCYCLES SEPRACOR INC. (US) 2010-02-04 US disclosed
US-20100022612-A1 FUSED HETEROCYCLES SEPRACOR INC. (US) 2010-01-28 US disclosed
US-7579370-B2 Fused heterocycles SEPRACOR INC. (US) 2009-08-25 US disclosed
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC. (US) 2008-03-06 US disclosed
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC. (US) 2008-03-06 US disclosed
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC. (US) 2008-03-06 US disclosed
WO-2008005456-A2 FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-10 WO disclosed
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-03 US disclosed
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-03 US disclosed
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-03 US disclosed
US-20080004328-A1 FUSED HETEROCYCLES SEPRACOR INC. (US) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022612-A1 FUSED HETEROCYCLES AHR, HAX1, HRH3 DAO 2452/4885PDE3B 4520/4885PDE3A 4599/4885
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase DAO, DDO, AOX1 DAO 1/4885PDE3B 1680/4885PDE3A 1538/4885
US-20100029741-A1 FUSED HETEROCYCLES CHRNA4, CHRNB4, CHRNA3 DAO 1545/4885PDE3B 2888/4885PDE3A 3201/4885
US-20080004328-A1 FUSED HETEROCYCLES HRH3, HRH4, AHR DAO 2936/4885PDE3B 4687/4885PDE3A 4670/4885
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE DAO, DDO, AOX1 DAO 1/4885PDE3B 3171/4885PDE3A 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.